Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder, breast and gastric cancers, evidence for the role of MIM in tumor progression remains scarce and controversial. Herein we characterized a MIM knockout mouse strain and observed that MIM-deficient mice often developed enlarged spleens. Autopsy and histological analysis revealed that nearly 78% of MIM(À/À) mice developed tumors with features similar to diffuse large B lymphoma during a period from 1 to 2 years. MIM(À/À) mice also exhibited abnormal distribution of B cells in lymphoid organs with decrease in the spleen but increase in the bone marrow and the peripheral blood. Furthermore, the bone marrow of MIM(À/À) mice contained a higher percentage of pre-B2 cells but fewer immature B-cells than wild-type mice. In response to CXCL13, a B-cell chemokine released from splenic stromal cells, MIM-deficient B-cells did not undergo chemotaxis or morphological changes in response to the chemokine and also did not internalize CXCR5, the receptor of CXCL13. Microarray analyses demonstrated that MIM is the only member of the I-BAR domain family that was highly expressed in human B cells. However, low or absent MIM expression was common in either primary B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas. Thus, our data demonstrate for the first time an important role for MIM in B-cell development and suggest that predisposition of MIM-null mice to lymphomagenesis may involve aberrant interactions between B lineage cells and the lymphoid microenvironment.
Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder, breast and gastric cancers, evidence for the role of MIM in tumor progression remains scarce and controversial. Herein we characterized a MIM knockout mouse strain and observed that MIM-deficient mice often developed enlarged spleens. Autopsy and histological analysis revealed that nearly 78% of MIM(À/À) mice developed tumors with features similar to diffuse large B lymphoma during a period from 1 to 2 years. MIM(À/À) mice also exhibited abnormal distribution of B cells in lymphoid organs with decrease in the spleen but increase in the bone marrow and the peripheral blood. Furthermore, the bone marrow of MIM(À/À) mice contained a higher percentage of pre-B2 cells but fewer immature B-cells than wild-type mice. In response to CXCL13, a B-cell chemokine released from splenic stromal cells, MIM-deficient B-cells did not undergo chemotaxis or morphological changes in response to the chemokine and also did not internalize CXCR5, the receptor of CXCL13. Microarray analyses demonstrated that MIM is the only member of the I-BAR domain family that was highly expressed in human B cells. However, low or absent MIM expression was common in either primary B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas. Thus, our data demonstrate for the first
Introduction
Metastasis suppressors negatively regulate a broad set of cellular activities pertinent to metastasis, such as tumor cell spreading, dormancy, angiogenesis and survival in new microenvironments (Bodenstine and Welch, 2008) . Like tumor suppressors, expression of metastasis suppressors is often reduced in metastatic cells as compared with non-metastatic counterparts. One such metastasis suppressor is the missing in metastasis (MIM; also known as metastasis suppressor 1) gene, expression of which is frequently silent in a subset of metastatic cell lines originating from bladder, breast and prostate cancers (Lee et al., 2002; Nixdorf et al., 2004; Loberg et al., 2005; Parr and Jiang, 2009 ). Recent studies with human cancers have revealed that the loss of MIM expression occurs in 69% of advanced bladder cancers (Wang et al., 2007) and 88% of metastatic gastric cancers (Liu et al., 2010) . Also, MIM expression is considerably upregulated by TBX5, a newly identified tumor suppressor in colon cancers . In breast and gastric cancers, low levels of MIM expression correlate with poor prognosis and may have predictive value for the disease-free survival (Parr and Jiang, 2009; Liu et al., 2010) . However, evidence supporting a pathological role of MIM in tumorigenesis remains fragmentary and sometimes controversial. For example, overexpression of MIM and amplification of the human MIM locus at human chromosome 8q24.1 was found in hepatocellular carcinomas and ovarian carcinomas, respectively Nowee et al., 2007) , and increased MIM immunoreactivity was associated with advanced colorectal cancers (Wang et al., 2011) . MIM was also identified as a Sonic hedgehog responsive gene (Callahan et al., 2004) , a signaling pathway normally implicated in tumorigenesis (Bailey et al., 2007) . In this study, we characterized a MIM-knockout (KO) mouse strain and observed a defect in the motility of MIMdepleted B cells in response to a splenic chemokine and efficient recruitment to the spleen. Furthermore, the aging MIM-KO mice have a predisposition to the formation of B-cell lymphoma. Our data suggests that MIM has a unique role in the development and function of B lymphocytes, and MIM depletion may promote lymphomagenesis through eliciting aberrant interactions between B lineage cells and their microenvironment.
Results and discussion
We have recently generated a complete MIM-KO mouse strain using a gene-trapping vector (Yu et al., 2011) . MIM(À/À) mice developed normally and were fertile, but the survival rate of MIM(À/À) mice was significantly lower than that of wild-type mice. The majority of the homozygous KO animals died between 14 to 24 months, and heterozygous mice also died slightly earlier than wild-type animals ( Figure 1a) . Biopsies of many sick or moribund old animals revealed that they had developed abnormal tissue structures (Table 1) . Notably, 81% of the animals had enlarged spleens (Table 1 , Supplementary Figure S1A ), which were also seen in young mice at the ages between 4 to 8 weeks (Figure 1b) . The splenomegaly was not due to a possible increase in their sizes because the body weight of MIM(À/À) mice was apparently normal at young (Figure 1c ) or old ages (data not shown). In addition to enlarged spleens, 56% of the aged animals also exhibited hepatomegaly with rough liver surfaces (Table 1, Supplementary Figure  S1B ), although hepatomegaly was not observed in young mice. Also, about 70% MIM(À/À) mice developed enlarged lymph nodes or spleens infiltrated by abnormal lymphoid cells with vesicular nuclei, abundant cytoplasm and small nucleoli (Figure 2a ), a morphology that was distinct from normal lymphocytes in lymph nodes or spleen (Figures 2c and d) , and was consistent with murine diffuse large B lymphoma according to Bethesda classifications (Morse et al., 2002) . The majority of the infiltrating cells expressed CD20 (Figure 2b and Supplementary Figure S2A ) or B220 (Supplementary Figure S2B ), but were negative for CD3, a T-cell marker (data not shown). The tumor cells expressed CD19 (B-cell marker) and CD5 (expressed in naı¨ve and memory B lymphomas; Supplementary Figure  S3A ), indicating that they were derived from CD5 þ Bcells. To determine the monoclonal nature associated with malignant lymphomas, the tumors harvested from three MIM(À/À) mice were analyzed by PCR for the VDJ rearrangement of immunoglobulin (Ig) heavy chain genes. As shown in Supplementary Figure S3B , the genomic DNA from a wild-type spleen yielded three prominent PCR products of 1.3 kb, 1.0 kb and 0.7 kb corresponding to DJ H 1, DJ H 2 and DJ H 3 Ig gene rearrangements, respectively (Chang et al., 1992) . 
Abbreviations: AN, abnormal; F, female; L, enlarged; Lm, lymphoma; M, male; N, normal; ND, not determined. Inflammation was identified by leukocyte infiltration into organs such as liver and kidney.
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Another expected band of 0.12 kb corresponding to DJ H 4 was barely detectable, presumably due to low resolution in the agarose gel. However, the DNAs of three lymphomas generated only one dominant PCR product, which migrated at the position of DJ H 3, indicating that these tumors were monoclonal. Some aged MIM(À/À) mice also displayed infiltrated leukocytes in the liver and the kidney (Table 1) , which contained a mixture of small T and B cells (Supplementary Figures S2E and F) . MIM was highly expressed in murine splenic B cells but weakly in splenic T cells (Figure 3a ). Because lymphomas are often associated with aberrant differentiation of B cells (Shaffer et al., 2002) , we thought that MIM depletion could affect B-cell development in different lymphoid organs. Indeed, about 50% decrease in the percentage of CD19 þ B cells in the spleen of MIM(À/À) mice was observed (Figures 3b and c) . Conversely, the population of B cells was increased by B20% in the bone marrow and more significantly in the peripheral blood of MIM(À/À) mice (Figure 3c ). Complete blood count analysis revealed normal ranges of most types of hematopoietic cells in MIM(À/À) mice, although the count of white blood cells in MIM(À/À) mice was evidently higher than that of wild-type mice (Supplementary Table S1 ). We also analyzed several markers of early B-cell development stages in the bone marrow. While bone marrow of MIM(À/À) mice contained a normal percentage of pre-B1 cells (CD19 þ CD117 þ /CD25 À ; Martensson et al., 2010; Rolink, 2004) , the percentage of pre-B2 cells B-cell development is guided by a series of interactions between B lineage cells and a variety of cytokines or chemokines released from stromal cells in the bone marrow and lymphoid organs (LeBien and Tedder, 2008) . We therefore examined the response of naı¨ve splenic B cells to CXCL13, a primary B-cell chemokine normally released from splenic stromal cells. In Transwell chambers, wild-type B cells had nearly fivefold higher directional migration towards the CXCL13-containing chamber. Yet, MIM(À/À) B cells failed to do so under the same conditions (Figures 4d and e) even though they expressed a normal level of CXCR5, the receptor for CXCL13 (Supplementary Figure S4) . It was also possible that the impaired motility response was caused by the targeting vector used in the generation of this mouse strain (Yu et al., 2011 ). Yet, the hetero- zygous B cells, which contained a single copy of the targeting vector, migrated slightly slower than wild-type cells, the difference was not statistically significant ( Figure 4f) .
We have recently observed that MIM-depleted embryonic fibroblasts were less polarized and partially impaired in the receptor-mediated endocytosis (Yu et al., 2011) . To examine whether MIM depletion also affects B-cell shape changes, we inspected splenic B cells in response to CXCL13 by phase microscopy. While nearly 57% of wild-type B cells were markedly polarized upon CXCL13 treatment, the majority of MIM(À/À) B cells retained their rounded morphology (Supplementary Figure S5 ). We also examined endocytosis of CXCR5 and found that MIM(À/À) B cells failed to internalize the receptor after they were exposed to CXCL13 for 20 min (Supplementary Figure S4) . These data suggest that MIM is required for B cells to respond to chemokines by modulation of cell shapes and endocytosis, and that MIM depletion may impair B-cell development by evoking an aberrant communication between B cells and stromal cells. To determine whether MIM has a role in human B cells, we analyzed the expression of MIM and other I-BAR (Bin-Amphiphysin-Rvs) domain family members (Abba, IRSp53, IRTKS and FLJ22582) in a series of hematopoietic cells from healthy adult blood donors, including B cells, T cells, monocytes and granulocytes (Figure 5a ). Although the transcripts of all other I-BAR domain genes were nearly undetectable, MIM transcripts were readily identified in primary B cells but much less prominent in monocytes, T cells and granulocytes. Compared with T cells, the level of MIM expression in B cells was about 16-fold higher, a result that agrees with the study with mouse samples (Figure 3a) , suggesting that MIM in B cells has a unique function. Next, we analyzed 11 human B acute lymphoblastic leukemia (B-ALL) cases and detected the majority (73%) of the samples contained low levels of MIM expression (Figure 5b) . Furthermore, there were negligible amounts of MIM transcripts in nine B-ALL cell lines (Figure 5b ). In screening of seven human and one murine B lymphoma cell lines, we only detected a weak level of MIM protein in SU-DHL-6 B-cells (Figure 5c ). We also failed to detect abundant MIM protein in a B-cell lymphoma from a patient (Supplementary Figure S6, lane a) . Thus, low or no MIM expression is common in these B-cell malignancies.
The mammalian MIM gene encodes a protein product containing an N-terminal region of 250 amino acids that is structurally similar to that of IRSp53 and distantly related to BAR domain, a motif that is present in a series of membrane modeling proteins (Gallop and McMahon, 2005; Frost et al., 2009) . As the BAR domains of MIM and IRSp53 have a unique zeppelinlike structure with the membrane binding surface on the convex face (Millard et al., 2005; Lee et al., 2007; Scita et al., 2008) , they have been recently used to define a subfamily of the BAR domain proteins as inverse BAR (I-BAR) domain family, including MIM, Abba, IRSp53, IRTKS and FLJ22582. In vitro studies have documented the role of MIM in membrane curvature, which is broadly related to cell migration, endocytosis and cell-substratum interactions (Woodings et al., 2003; Bompard et al., 2005; Lin et al., 2005; Mattila et al., 2007) . Recent studies with other MIM-KO murine strains also indicated a role of MIM in the intercellular interaction in the kidney cells (Xia et al., 2010; Saarikangas et al., 2011 ). Yet, the role of MIM in the modulation of cell migration appears to be complex. We had previously shown that overexpression of a MIM construct inhibited cell migration in response to extracellular stimuli (Lin et al., 2005) . Similarly, suppression of MIM by RNA interference increased the locomotion of breast cancer cells in vitro (Parr and Jiang, 2009 ). On the other hand, a Drosophila mutant with depletion of dMIM expression exhibited a defect in a directional motility of border cells (Quinones and Oro, 2010) , suggesting that MIM acts differently under physiological conditions. Consistent with this finding, we also observed here a defect in the motility response of MIM(À/À) B cells to CXCL13, the signaling of which is required for B cells to home to lymphoid follicles in the spleen and Peyer patches, and for lymphoid organ development (Lipp and Muller, 2004) . Inability to respond to CXCL13 may partially explain the increased accumulation of B cells in the peripheral blood and the decrease in the spleens of MIM-KO mice. As MIM is an intracellular protein and regulates the actin cytoskeletonmediated membrane dynamics, MIM deficiency may affect signaling pathways of other types of chemokines released from stromal cells in the bone marrow, and thereby possibly influencing B-cell differentiation at an earlier stage such as the transition from pre-B2 to immature B cells as detected herein. However, we could not rule out completely the possibility that the targeting event in our MIM-KO mice may create these phenotypes through a secondary and unknown mechanism. Improper interactions of stem cells or progenitors with stromal cells have been associated with cancers including human lymphoma (Mahadevan et al., 2005; Egeblad et al., 2010; Gribben, 2010) and murine lymphoma (Middendorp et al., 2009) . Furthermore, upregulated chemokine signaling pathways are thought to promote tumor progression by driving leukocyte infiltration and angiogenesis, and by establishing a tumor milieu favoring metastases (Karnoub and Weinberg, 2006 ). Yet, we show here that MIM is necessary for the migration of B cells toward CXCL13, a primary chemokine for B cells, and increased response to chemokines is often associated with metastases (McAllister and Weinberg, 2010) . It is also paradoxical to observe extensive lymphoid infiltrates in various organs with MIM(À/À) mice. One possibility is that the MIMmediated response to chemotactic factors is not directly involved in the infiltration of all the leukocytes into peripheral organs and may be limited to specific types of cells in response to specific extracellular cues. Indeed, in one case we found that an infiltrate in the liver of a MIM(À/À) mouse was more dominated by T cells than B cells. It is also interesting to observe MIM(À/À) embryonic fibroblasts, which expressed modest amounts of MIM, had a normal motility in the presence of growth factors but were only impaired under conditions with low percentages of serum (Yu et al., 2011) . Thus, it appears that MIM regulates cellular motility differently depending upon microenvironments. This plastic property could provide an advantage to stem cells or progenitors during their transition to malignancies under a pathological condition. For example, reduced MIM expression might impair a normal stem cellstroma interaction and lead to improper homing of stem cells or progenitor cells to a location that would otherwise protect them from unwanted hazards but release chemotactic signals in which the function of MIM is not necessary. Consequently, this mismatch between progenitor cells and their microenvironment might increase their susceptibility to oncogenic insults and their chances to become cancer-initiating cells after accumulation of mutational hits. MIM depletion may affect other signaling pathways implicated in lymphomagenesis. Notably, MIM is implicated in the signaling of Sonic hedgehog, which has been found to have a critical role in the interaction between lymphoma and their immune microenvironment (Dierks et al., 2007; Lindemann, 2008) . Although the exact role of MIM in hedgehog pathways in vivo remains undefined (Liu et al., 2011; Saarikangas et al., 2011) , MIM may act in negative concert with hedgehog proteins in B cells, and MIM depletion may facilitate the response of neoplastic B cells to hedgehogs. In the preparation of this manuscript, Liu et al. (2011) has reported that frog MIM protein is associated with Daam1, a formin family protein that is implicated in the actin polymerization and acts as a signaling factor downstream of Wnt5a. Interestingly, mice with depletion of Wnt5a were also prone to lymphomagenesis (Liang et al., 2003) , suggesting of an alternative link from MIM depletion to lymphoma progression.
Materials and methods

Antibodies
Polyclonal MIM antibody was described previously (Lin et al., 2005) . Anti-CD20 antibody was purchased from Millipore (Billerica, MA, USA); anti-B220, anti-Thy1, anti-CD4 and anti-CD8 antibodies were provided by Dr David Scott; anti-CD3 antibody from Calbiochem (Gibbstown, NJ, USA); allophycocyanin-conjugated anti-CD19, phycoerythrin-conjugated anti-CD25, and fluorescein isothiocyanate-conjugated anti-CD117 were from Biolegend (San Diego, CA, USA). fluorescein isothiocyanate-conjugated anti-IgM was from Southern Biotech (Birmingham, AL, USA). phycoerythrin-conjugated anti-IgD was from eBioscience (San Diego).
Animals
Generation of MIM-KO mice has been described (Yu et al., 2011) . The KO mice have been back crossed with C57BL/6 for 7-9 generations to reach a nearly homogenous genetic background and been bred in the vivarium facility at University of Maryland Baltimore. All the animal experiments were conducted in compliance with protocols instituted by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine.
Histological analysis
Mice were euthanized at the age of 14-28 months and examined at necropsy for the presence of tumors. Tumors and tissue organs including the spleen, lymph nodes, thymus, lung, liver, femur, kidney, brain, pancreas, intestine, colon and the heart were dissected, fixed and stained with hematoxylin and eosin as described previously (Wang et al., 2007) . Sections were examined microscopically and the presence of lymphoma was identified according to the Bethesda classification (Morse et al., 2002) . To determine the B-cell origin of the lymphomas, sections containing lymphomas were immunostained with anti-CD20, B220 and CD3 antibodies, respectively, as described previously (Wang et al., 2007) .
Western blot
Splenic B-cells were purified according to the procedure as described previously (Su et al., 2008) . Briefly, spleens were dissected from the animals and minced. The resulting non-adherent cells were collected in B-cell medium (RPMI (Roswell Park Memorial Institute) 1640 medium supplemented with 5% fetal bovine serum, 2 mM L-glutamine and 50 mM b-mecaptoethanol), and were incubated with anti T-cell mixture (anti-Thy1, anti-CD4 and anti-CD8) for 30 min followed by treatment with Low Tox complement (Cedarlane Laboratories, Burlington, NC, USA) according to the manufacturer's instruction. Purified B cells were lysed in SDS sample buffer and subject to 8% SDS-polyacrylamide gel followed by immunoblotting using anti-MIM polyclonal antibody (Wang et al., 2007) . Equal protein loading on gels was confirmed by anti-actin antibody.
To isolate human B cells, mononuclear cells were isolated from peripheral blood and incubated with magnetic beads coated with CD19 monoclonal antibody for 3 min at 4 1C. The magnetic beads were collected, washed with PBS and further incubated in RPMI1640 medium at 37 1C in an atmosphere of 5% CO 2 . The magnetic beads were separated from CD19 þ B cells by using Dynal MPC device (Dynal Biotech, Oslo, Norway).
A human lymphoma specimen was obtained as a lymph node biopsy from a patient with B-cell lymphoma with informed consent under an Institutional review boardapproved human subject research protocol.
Flow cytometry
Cells isolated from bone marrow or spleen were incubated with appropriate surface marker antibodies for 40 min at 4 1C, washed once with PBS containing 0.5% bovine serum albumin and analyzed on FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed with Flowjo software (Ashland, OR, USA).
Cell motility assay B-cell migration was analyzed using Costar Transwell plates with 5-mm pore size (Corning, Lowell, MA, USA). Briefly, 10 6 B-cells suspended in 100 ml of B-cell medium were loaded into the upper chamber of a Transwell plate. The lower chamber was loaded with 600 ml of the same medium containing 1 mg/ml CXCL13. In a different experiment, a range of CXCL13 concentrations from 0 to 1 mg/ml was used. The control sample was set up with the lower chamber containing the medium alone. The plate was incubated at 37 1C with constant 5% CO 2 supply. After 2 h of incubation, the upper chambers were removed and the cells that had migrated into the lower chamber were counted with hemocytometer. The percentage of migrated cells was calculated by dividing the number of cells collected in the lower chamber by the total cell number loaded into the plate at the initial set up.
Analysis of the clonality of lymphomas Genomic DNAs were purified from formaldehyde-fixed tissues with FFPE Tissue Kit (Qiagen, Venlo, Netherlands, cat# 56 404) or from fresh tumors with DNeasy kit (Qiagen, cat#695 060). The purified DNAs were used as the templates in PCR using DSF and JH4 primers specific for mouse DJ DNA arrangement (Chang et al., 1992) . DSF primer: 5 0 -AGG GATCCTTGTGAAGGGATCTACTACTGTG-3 0 ; JH4 primer: 5 0 -AAAGACCTCCAGAGGCCATTCTTACC-3 0 . PCRs were carried out using Pfuturbo DNA polymerase (Stratagene, La Jolla, CA, USA) under the condition: 35 cycles of 95 1C 30 s, 61.5 1C 30 s, 72 1C 1 min and followed by 72 1C 10 min for extension.
Microarray and data analysis Microarray expression analysis was performed using the Affymetrix GeneChip Human Gene 1.0. ST Array, which contains 764 885 probes representing 28 869 annotated genes. We analyzed a total of 9 nine B-ALL cell lines, each repeated three times, 11 primary precursor B-ALL patient samples, 4 samples of primary human peripheral blood CD19 þ B cells, 8 samples of primary normal human peripheral blood T cells, 4 samples of primary normal human peripheral blood granulocytes and 2 samples of primary normal human peripheral blood monocytes. Microarray data analyses were performed using GeneSpring GX software (Agilent Technologies, Columbia, MD, USA).
Analysis of CXCR5 endocytosis I all, 5 Â 10 6 spleenocytes were incubated in B-cell medium with or without 1 mg/ml CXCL13 at 37 1C in 5% CO 2 for 20 min, cells were then placed on ice, washed twice with icecold RPMI1640 containing 0.5%. BSA, and stained at 4 1C with allophycocyanin-CD19 and phycoerythrin-Cy7-CXCR5 mAbs (R&D Systems, Minneapolis, MN, USA), and analyzed by flow cytometry.
